Positive CAR-exosome data in ovarian cancer

Summary by 6ix AI

Inoviq Ltd has announced positive in vitro results demonstrating the tumour-killing activity of its CAR-exosomes in ovarian cancer cell lines. These findings support the potential of Inoviq's CAR-exosome platform for treating various hard-to-treat solid tumours, including triple negative breast cancer and non-small cell lung cancer. The company is advancing its manufacturing readiness and expects new data on dual-action CAR-exosomes in the near future.

Written by 6ix AI from the company’s filing. How 6ix writes summaries